Cost-effectiveness analysis of nivolumab in the second-line treatment of metastatic clear cell renal cell carcinoma
- VernacularTitle:纳武利尤单抗二线治疗转移性肾透明细胞癌的成本-效果分析
- Author:
Yingdan CAO
1
,
2
;
Fenghao SHI
1
,
2
;
Rui MENG
1
,
2
;
Pingyu CHEN
1
,
2
;
Zhengyang FEI
1
,
2
;
Xueke ZHANG
1
,
2
;
Aixia MA
1
Author Information
1. School of International Pharmaceutical Business，China Pharmaceutical University，Nanjing 211198，China
2. Evaluation and Research Center of Pharmacoeconomics，China Pharmaceutical University，Nanjing 211198，China
- Publication Type:Journal Article
- Keywords:
nivolumab;
metastatic clear cell renal cell carcinoma;
everolimus;
partitioned survival model;
cost-effectiveness
- From:
China Pharmacy
2022;33(10):1233-1239
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To ev aluate the economical efficiency of nivolumab versus everolimus in the second-line treatment of metastatic clear cell renal cell carcinoma. METHODS From the perspective of China ’s health system ，cost-effectiveness analysis of the two therapies was carried out by developing a three-state partitioned survival model. The clinical parameters were from the updated CheckMate 025 study，and the cost and health utility were from relevant websites and published literatures. The model adopted a 2-week cycle and a lifetime research time. The robustness of the results was verified by sensitivity analysis. The economical efficiency of two therapy schemes were evaluated in the scenario of model simulation time of 80 months and charitable drug donation scheme. RESULTS The results of basic analysis showed that compared with everolimus ，the incremental cost-effectiveness ratio （ICER）of nivolumab was 586 982.60 yuan/quality-adjusted life year （QALY），which was far higher than 3 times of China ’s per capita gross domestic product （GDP）in 2020. The results of single-factor sensitivity analysis showed that the 3 parameters that had the greatest impact on the economic evaluation results were the cost of nivolumab ，the utility value of nivolumab group and everolimus group in progressive disease state. The results of probability sensitivity analysis verified the robustness of the basic analysis results. Results of scenario analysis showed that in the first scenario analysis ，in which model simulation time lasted for 80 months，ICER of nivolumab was 417 204.52 yuan/QALY；in the second scenario analysis ，in which nivolumab charitable drug donation program for low-income people was considered ，ICER of nivolumab was 124 988.58 yuan/QALY. CONCLUSIONS Under the threshold of 1-3 times of China ’s per capita GDP in 2020，compared with everolimus ，it is not economical to use nivolumab as the second-line treatment for metastatic clear cell renal cell carcinoma ； nivolumab is economical when considering its charitable drug donation program for low-income people.
